Date: 2011-10-26
Type of information: Private placement
Company: OctoPlus (the Netherlands)
Investors:
Amount: €4 million
Funding type: private placement
Planned used: OctoPlus intends to use the proceeds of the private placement for working capital purposes and to retain upside by co-investing along with clients in selected high-value projects in the area of specialty generics.
Others: Octoplus has successfully completed an equity raising with €4 million gross proceeds through a private placement of 8 million shares at an offer price of € 0.50 per share with new and existing investors. In the context of the Offering 8 million new ordinary shares with a nominal value of € 0.12 will be issued and following such issue, the Company will have 44.778.974 shares in issue. The Company\'s CEO Mr. Jan Hendrik Egberts purchased 300.000 shares in the Offering. The Offering shall be structured as a private placement. The offer price of the ordinary shares offered is €0.50 per share (the \"Offer Price\"). OctoPlus swaps an amount of new shares that is equal to the number of shares offered in the Offering with three major shareholders in exchange for an equal number of existing ordinary shares of OctoPlus currently held by these shareholders. The existing ordinary shares, which are delivered to OctoPlus, will be placed by OctoPlus in a non-pre-emptive placement with qualified investors in the Netherlands and elsewhere in the framework of the Offering. A number of the Company\'s existing shareholders, including the Company\'s CEO, Mr. Jan Hendrik Egberts, and certain new investors have committed themselves to subscribe for shares in the Offering for a substantial part of the amount that OctoPlus aims to raise, subject to €4 million in gross proceeds being raised. The new ordinary shares will rank pari passu in all respects with OctoPlus\' existing issued ordinary shares and in order to ensure that the new ordinary shares are marketable on the stock exchange of NYSE Euronext in Amsterdam OctoPlus will procure to have the new ordinary shares listed and admitted to trading on NYSE Euronext in Amsterdam on or before the date that is 90 days after the settlement of the Offering on the basis of a prospectus to be prepared by OctoPlus and be approved by the Dutch Authority for the Financial Markets (AFM) and in accordance with the rules and regulations of NYSE Euronext in Amsterdam.
Therapeutic area: Technology - Services
